奥拉西坦联合脑蛋白水解物治疗脑卒中后认知功能障碍的临床疗效及对血清Hcy、hs-CRP水平的影响  

Oxiracetam combined with cerebroprotein hydrolysate injection for treating cognitive dysfunction after stroke and its influence on serum Hcy and hs-CRP levels

作　　者：刘倩[1] 付本升[1] 钟毓贤[1] 王宇[1] 丁宇[1] 

机构地区：[1]中国人民解放军海军总医院康复医学科,北京100048

出　　处：《广西医科大学学报》2017年第12期1748-1751,共4页Journal of Guangxi Medical University

摘　　要：目的:探讨奥拉西坦联合脑蛋白水解物治疗脑卒中后认知功能障碍的临床疗效及对患者血清同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)水平的影响。方法:选取2016年1月至2017年1月中国人民解放军海军总医院收治的脑卒中后认知功能障碍患者127例,按照随机数字表法将其分为对照组(64例)和观察组(63例)。对照组采用脑蛋白水解物单独治疗,观察组采用脑蛋白水解物与奥拉西坦联合治疗,采用蒙特利尔认知功能评估量表(MoCA)、简易智能状态量表(MMSE)、日常生活能力量表(ADL)对患者治疗后的认知功能、智力及生活能力进行评价,采用酶联免疫吸附试验(ELISA)法检测患者血清神经元特异性烯醇化酶(NSE)、S100β蛋白、Hcy水平,采用免疫比浊法检测血清hs-CRP水平,记录两组不良反应发生情况。结果:观察组临床总有效率明显高于对照组(P<0.05)。两组治疗后MoCA、MMSE、ADL评分均较治疗前明显升高(P<0.05),且观察组治疗后MoCA、MMSE、ADL评分均高于对照组(P<0.05);两组治疗后血清NSE、S100β、Hcy、hs-CRP水平均较治疗前明显降低(P<0.05),且观察组治疗后NSE、S100β、Hcy、hs-CRP水平均明显低于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:奥拉西坦联合脑蛋白水解物能够明显改善脑卒中术后认知功能障碍,降低患者血清Hcy、hs-CRP水平,值得临床推广。Objective： To investigate the efficacy of oxiracetam combined with cerebroprotein hydrolysate injection for treating cognitive dysfunction after stroke and its influence on serum homocysteine（Hcy）and high-sensitivity C-reactive protein（hs-CRP）levels. Methods： A total of 127 patients with postoperative cognitive impairment treated in our hospital from January 2016 to January 2017 were enrolled and randomly divided into a control group（64 cases）and an observation group（63 cases）. The patients in the control group received cerebroprotein hydrolysate injection,and those in the observation group received cerebroprotein hydrolysate injection combined with oxiracetam. The cognitive function,intelligence and daily living ability of the patients were evaluated by Montreal cognitive assessment（MoCA）,mini-mental state examination（MMSE）and activities of daily living（ADL）scale,respectively.The levels of neuron specific enolase（NSE）,S100β protein and Hcy in the serum were detected by enzyme linked immunosorbent assay（ELISA）. Immunoturbidimetry was used to measure the hs-CRP level. The incidence of adverse events was recorded. Results： The total effective rate,and the scores of Mo CA,MMSE and ADL in the observation group were significantly higher than those in the control group,while the levels of NSE,S100β,Hcy and hs-CRP were significantly lower（P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups（P〉0. 05）. Conclusion： Oxiracetam combined with cerebroprotein hydrolysate injection could effectively improve cognitive dysfunction after stroke,and reduce serum Hcy and hs-CRP levels.

关 键 词：脑蛋白水解物 奥拉西坦 脑卒中 认知障碍 临床疗效 

分 类 号：R743.3[医药卫生—神经病学与精神病学]